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Volume 57, Number 5S Abstracts 69SResults: EVPAR was performed in 46 limbs, 38
patients, elective: 33 (72%), emergent: 13 (28%). One
aneurysm ruptured, 12 caused acute ischemia (12 under-
went thrombolysis+ EVPAR). Mean of 2.0 Viabahn
stent-grafts (range, 1-4) were used. Sixteen procedures
(35%) were performed percutaneously, 30 through femoral
cutdown. Technical success was 98%. Thirty-day mortality
was 4.4%, all after emergencies (15.4%, 2/13). Thirty-day
primary and secondary patencies were 100% for elective,
75% and 84%, respectively for emergencies. Two major
amputations (15.4%) were done after emergent EVPAR.
Early complications were more frequent after emergencies
(77% vs 12%; P < .0001). Intracranial hemorrhage
occurred in one patient (2.2%). Mean follow-up was 2.2
years (30 days-8.6 years). At 2 years, primary patencies
were 70% and 64% (P ¼ .44), secondary patencies 80%
and 84%, (P ¼ .79); no limb was lost in elective cases,
limb salvage was 84% for emergencies (P ¼ .02); reinter-
ventions were similar (19% and 30%); major adverse events
occurred after 20 procedures (44%) (elective, 38%; emer-
gent, 64%; P ¼ .01). There were 5 conversions (elective,
4; emergent, 1). Factors affecting adverse events included
emergent EVPAR and percutaneous placement.
Conclusions: PAA with acute presentation continues
to have elevated mortality (16%) and limb loss (16%).
Although elective EVPAR has excellent early results, 2-
year patency of 80% remains a concern.
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Objectives: The aim of this study was to investigate
the outcome following endovascular therapy(EVT) for
femoropopliteal(FP) lesion classiﬁed into TransAtlantic
Inter-Society Consensus (TASC) II class A and B.
Methods: This study was a multicenter retrospective
analysis. A total of 2742 consecutive patients (3471limbs)
with FP disease and 2003 limbs with TASCII class A and
B lesions were analyzed in current study; 1169 (58.4%)
were stenting, 834 (41.6%) were plain old balloon angio-
plasty (POBA) alone.
Results: The mean follow-up term were 4.6 6 0.1
years. The mean reference vessel diameter (RVD) was 58.7
6 33.8 mm and the mean lesion length was 5.2 6 1.0
mm. Primary patency was signiﬁcantly higher in the stent
group (85.3%, 69.6% and 59.9% at 1, 3 and 5 years) than
that in the POBA group (76.2%, 59.6% and 49.3% at 1, 3
and 5 years; P < .0001). Assisted primary patency was also
better in the stent group than that in the POBA group
(P ¼ .0002) and the difference in secondary patencybetween in the two groups was similarly signiﬁcant (P ¼
.006). Limited to lesions with RVD below 4.5 mm, there
was no difference in primary patency between in the two
groups (stent vs POBA; 73.0% vs 74.8%, 57.2% vs 53.2%
and 46.8% vs 45.4% at 1, 3 and 5 years; P ¼ .67). Diabetes,
hemodialysis, the history of cerebrovascular disease, absence
of cilostazol, POBA alone andRVD<4.5mmwere found to
be independent predictors of primary patency.
Conclusions: FP stenting improves the primary, assis-
ted-primary and secondary patency for the femoropopliteal
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Predictors of 30-Day Readmission and Postdischarge
Mortality Following Lower Extremity Amputation in
the ACS-NSQIP
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Objectives: Postoperative readmission is associated
with increased morbidity and mortality. We evaluated risk
factors for readmission and postdischarge adverse events
following lower extremity amputation in the ACS-NSQIP.
Methods: All patients undergoing transmetatarsal
(TMA), below-knee (BKA) or above-knee amputation
(AKA) in the 2011 NSQIP were identiﬁed. Independent
predictors of 30-day readmission were determined using
multivariable logistic regression.
Results: 3438 patients underwent amputation (TMA,
12%; BKA, 50%; AKA, 38%). Readmission rate was 18%.
Thirty-day mortality rate was 8.3% (TMA, 3%; BKA, 6%;
AKA, 13%; P < .01) with 44% of deaths occurring post-
discharge. Overall complication rate was 47% (in-hospital,
41%; postdischarge, 9%). Postdischarge complications
were readmitted in 71% of cases. Amputation level was
not associated with increased complication rate or readmis-
sion rate. Independent predictors of readmission included
OR take-back (OR, 7.0; 95% CI, 5.4-9.0), preoperative
